Cargando…

Consensus-based care recommendations for adults with myotonic dystrophy type 2

PURPOSE OF REVIEW: Myotonic dystrophy type 2 (DM2) is a rare, progressive multisystem disease particularly affecting the skeletal muscle. A causal therapy is not yet available; however, prompt, appropriate symptomatic treatments are essential to limit disease-related complications. Evidence-based gu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schoser, Benedikt, Montagnese, Federica, Bassez, Guillaume, Fossati, Barbara, Gamez, Josep, Heatwole, Chad, Hilbert, James, Kornblum, Cornelia, Kostera-Pruszczyk, Anne, Krahe, Ralf, Lusakowska, Anna, Meola, Giovanni, Moxley, Richard, Thornton, Charles, Udd, Bjarne, Formaker, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745739/ https://www.ncbi.nlm.nih.gov/pubmed/31583190 http://dx.doi.org/10.1212/CPJ.0000000000000645

Ejemplares similares

Core Clinical Phenotypes in Myotonic Dystrophies
por: Wenninger, Stephan, et al.
Publicado: (2018)

Editorial: Beyond Borders: Myotonic Dystrophies–A European Perception
por: Schoser, Benedikt, et al.
Publicado: (2018)

Validation of Motor Outcome Measures in Myotonic Dystrophy Type 2
por: Montagnese, Federica, et al.
Publicado: (2020)

Eight years after an international workshop on myotonic dystrophy patient registries: case study of a global collaboration for a rare disease
por: Wood, Libby, et al.
Publicado: (2018)

Myotonic Dystrophy—A Progeroid Disease?
por: Meinke, Peter, et al.
Publicado: (2018)

Correction to: Eight years after an international workshop on myotonic dystrophy patient registries: case study of a global collaboration for a rare disease
por: Wood, Libby, et al.
Publicado: (2019)

Clinical Outcome Evaluations and CBT Response Prediction in Myotonic Dystrophy
por: van As, Daniël, et al.
Publicado: (2021)

Current Progress in CNS Imaging of Myotonic Dystrophy
por: Minnerop, Martina, et al.
Publicado: (2018)

Dyslexia and cognitive impairment in adult patients with myotonic dystrophy type 1: a clinical prospective analysis
por: Gutschmidt, K., et al.
Publicado: (2020)

ZNF9 Activation of IRES-Mediated Translation of the Human ODC mRNA Is Decreased in Myotonic Dystrophy Type 2
por: Sammons, Morgan A., et al.
Publicado: (2010)

Myotonic Dystrophies 1 and 2: Complex Diseases with Complex Mechanisms
por: Schoser, Benedikt, et al.
Publicado: (2010)

The myotonic dystrophy experience: a North American cross‐sectional study
por: Hagerman, Katharine A., et al.
Publicado: (2019)

rbFOX1/MBNL1 competition for CCUG RNA repeats binding contributes to myotonic dystrophy type 1/type 2 differences
por: Sellier, Chantal, et al.
Publicado: (2018)

The Impact of Pregnancy on Myotonic Dystrophy: A Registry-Based Study
por: Johnson, Nicholas E., et al.
Publicado: (2015)

Nuclear Envelope Transmembrane Proteins in Myotonic Dystrophy Type 1
por: Hintze, Stefan, et al.
Publicado: (2018)

Genetic determinants of disease severity in the myotonic dystrophy type 1 OPTIMISTIC cohort
por: Cumming, Sarah A., et al.
Publicado: (2019)

Consensus-based care recommendations for adults with myotonic dystrophy type 1
por: Ashizawa, Tetsuo, et al.
Publicado: (2018)

Associations Between Variant Repeat Interruptions and Clinical Outcomes in Myotonic Dystrophy Type 1
por: Wenninger, Stephan, et al.
Publicado: (2021)

Editorial: Myotonic Dystrophies: Developments in Research From Bench to Bedside
por: Silvestri, Gabriella, et al.
Publicado: (2020)

TNNT2 Missplicing in Skeletal Muscle as a Cardiac Biomarker in Myotonic Dystrophy Type 1 but Not in Myotonic Dystrophy Type 2
por: Bosè, Francesca, et al.
Publicado: (2019)

CTG-Repeat Detection in Primary Human Myoblasts of Myotonic Dystrophy Type 1
por: Hintze, Stefan, et al.
Publicado: (2021)

Towards development of a statistical framework to evaluate myotonic dystrophy type 1 mRNA biomarkers in the context of a clinical trial
por: Kurkiewicz, Adam, et al.
Publicado: (2020)

Nuclear envelope transmembrane proteins involved in genome organization are misregulated in myotonic dystrophy type 1 muscle
por: Todorow, Vanessa, et al.
Publicado: (2023)

Quantitative Methods to Monitor RNA Biomarkers in Myotonic Dystrophy
por: Wojciechowska, Marzena, et al.
Publicado: (2018)

Myotonic dystrophy type 2: the 2020 update
por: Meola, Giovanni
Publicado: (2020)

Neuropsychological and Psychological Functioning Aspects in Myotonic Dystrophy Type 1 Patients in Italy
por: Callus, Edward, et al.
Publicado: (2018)

Aberrant insulin receptor expression is associated with insulin resistance and skeletal muscle atrophy in myotonic dystrophies
por: Renna, Laura Valentina, et al.
Publicado: (2019)

Clinical aspects, molecular pathomechanisms and management of myotonic dystrophies
por: MEOLA, GIOVANNI
Publicado: (2013)

Transcriptome Analysis in a Primary Human Muscle Cell Differentiation Model for Myotonic Dystrophy Type 1
por: Todorow, Vanessa, et al.
Publicado: (2021)

SCN4A as modifier gene in patients with myotonic dystrophy type 2
por: Binda, Anna, et al.
Publicado: (2018)

Myotonic dystrophy
por: Patterson, VH
Publicado: (1990)

Quantifying Cancer Absolute Risk and Cancer Mortality in the Presence of Competing Events after a Myotonic Dystrophy Diagnosis
por: Gadalla, Shahinaz M., et al.
Publicado: (2013)

Premature Senescence in Primary Muscle Cultures of Myotonic Dystrophy Type 2 is not Associated with p16 Induction
por: Renna, L.V., et al.
Publicado: (2014)

Rare Disease: Cardiac Risk Assessment With MRI in Patients With Myotonic Dystrophy Type 1
por: Alì, Marco, et al.
Publicado: (2020)

Combinatorial chloride and calcium channelopathy in myotonic dystrophy
por: Cisco, Lily A., et al.
Publicado: (2023)

Myotonic Dystrophies: State of the Art of New Therapeutic Developments for the CNS
por: Gourdon, Genevieve, et al.
Publicado: (2017)

Validation of plasma microRNAs as biomarkers for myotonic dystrophy type 1
por: Perfetti, A., et al.
Publicado: (2016)

Relationships between grip strength, myotonia, and CTG expansion in myotonic dystrophy type 1
por: Hogrel, Jean‐Yves, et al.
Publicado: (2017)

Benefits of aerobic exercise in myotonic dystrophy type 1
por: Mackenzie, Samuel J., et al.
Publicado: (2022)

Targeting DMPK with Antisense Oligonucleotide Improves Muscle Strength in Myotonic Dystrophy Type 1 Mice
por: Jauvin, Dominic, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_janefls787sneqm2pog40cudk6